2020-2021 Nationwide Blood Donor Seroprevalence Survey Infection-Induced Seroprevalence Estimates

Principal Investigator(s):  View help for Principal Investigator(s) United States Department of Health and Human Services. Centers for Disease Control and Prevention; Laboratory Surveillance

Version:  View help for Version V1

Name File Type Size Last Modified
2020-2021_Nationwide_Blood_Donor_Seroprevalence_Survey_Infection-Induced_Seropre.csv text/csv 449.7 KB 01/11/2026 11:43:AM
2020-2021_Nationwide_Blood_Donor_Seroprevalence_Survey_Infection-Induced_Seroprevalence_Estimates.pdf application/pdf 414 KB 01/10/2026 02:34:PM

Project Citation: 

United States Department of Health and Human Services. Centers for Disease Control and Prevention, and Laboratory Surveillance. 2020-2021 Nationwide Blood Donor Seroprevalence Survey Infection-Induced Seroprevalence Estimates. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2026-01-11. https://doi.org/10.3886/E243464V1

Project Description

Project Title:  View help for Project Title 2020-2021 Nationwide Blood Donor Seroprevalence Survey Infection-Induced Seroprevalence Estimates
Summary:  View help for Summary CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection and refers to the prevalence of the population with both anti-S and anti-N antibodies. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html Read less
Original Distribution URL:  View help for Original Distribution URL https://data.cdc.gov/Laboratory-Surveillance/2020-2021-Nationwide-Blood-Donor-Seroprevalence-Su/mtc3-kq6r/about_data

Scope of Project

Subject Terms:  View help for Subject Terms covid; covid-19; covid19; coronavirus; laboratory; prevalence; sars-cov; seroprevalence; serosurveys; ncird-corvd
Collection Notes:  View help for Collection Notes (Downloaded 1/10/2026)


Related Publications

Download this project

Published Versions

V1 [2026-01-11]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as received from the data depositor. ICPSR has not reviewed, checked, or processed this material. For additional information about the study, please contact the investigator(s) directly. If you have questions about the accessibility of materials distributed by ICPSR or require further assistance, please visit ICPSR's Accessibility Center.